Treating NPC - Strategies for Recurrent and Metastatic Disease
June 12th 2025Panelists discuss the standard management of recurrent/metastatic nasopharyngeal carcinoma (NPC), emphasizing surgery or re-irradiation when feasible, and gemcitabine-cisplatin chemotherapy as the systemic backbone, while highlighting the need for more effective therapies to improve long-term outcomes.
Read More
An Overview to NPC: From Disease Biology to Treatment Approaches
June 12th 2025Panelists discuss the distinct Epstein-Barr virus (EBV)-driven biology of nasopharyngeal carcinoma (NPC), the role of plasma EBV DNA as a biomarker, and the strong evidence supporting gemcitabine-based induction chemotherapy followed by chemoradiotherapy as standard treatment for locally advanced disease.
Read More
Dr. Burtness on the Future of Immunotherapy in Head and Neck Cancer
August 29th 2019Barbara Burtness, MD, professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program; co-director, Developmental Therapeutics Research Program; of Yale Cancer Center, discusses the future of immunotherapy in head and neck cancer.
Read More
Dr. Burtness on the Use of Biomarkers in Metastatic HNSCC
April 29th 2019Barbara Burtness, MD, professor of Medicine (Medical Oncology) Disease Aligned Research Team Leader, Head and Neck Cancers Program co-director, Developmental Therapeutics Research Program of Yale Cancer Center, discusses the use of biomarkers in metastatic head and neck squamous cell carcinoma.
Read More
Dr. Burtness on Promise of Frontline Pembrolizumab in Metastatic HNSCC
March 30th 2019Barbara Burtness, MD, professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program; co-director, Developmental Therapeutics Research Program; of Yale Cancer Center, discusses the promise of frontline pembrolizumab in the treatment of patients with metastatic head and neck squamous cell carcinoma.
Read More
Dr. Burtness on the Benefit of Pembrolizumab in Head and Neck Cancer
December 1st 2018Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses the benefit of pembrolizumab (Keytruda) as a treatment for patients with recurrent metastatic head and neck squamous cell carcinoma.
Read More
Dr. Burtness on Treatment Approaches in HPV-Positive Head and Neck Cancer
December 27th 2016Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses current treatment approaches for patients with human pappillomavirus (HPV)-positive head and neck cancer, as well as potential changes for those regimens.
Read More
Dr. Burtness on the Use of Immunotherapy After Chemoradiation in Head and Neck Cancer
December 15th 2016Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the use of immunotherapy in patients with head and neck cancer who have residual disease following treatment with chemotherapy and radiation.
Read More